A versatile prodrug approach for liposomal core-loading of water-insoluble camptothecin anticancer drugs

被引:39
作者
Liu, XL
Lynn, BC
Zhang, JH
Song, L
Bom, D
Du, W
Curran, DP
Burke, TG [1 ]
机构
[1] Univ Kentucky, Dept Chem, Lexington, KY 40506 USA
[2] Univ Kentucky, Dept Pharmaceut Sci, Lexington, KY 40506 USA
[3] Univ Kentucky, Lucille P Markey Canc Ctr, Expt Therapeut Program, Lexington, KY 40506 USA
[4] Tigen Pharmaceut Inc, Lexington, KY 40508 USA
[5] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA
关键词
D O I
10.1021/ja0256212
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
We describe a versatile prodrug strategy for loading the liposomal lumen with water-insoluble camptothecins. The procedure involves conversion of an active camptothecin analogue to a 20-OR ω-aminoalkanoanic ester prodrug in which R = CO[CH2]nNH2 and n = 1-3. The basic amino group of the prodrug serves three roles. First, at pH ranges of 3-5, the amine enhances aqueous solubility. Second, it enhances responsiveness to a transmembrane ammonium sulfate gradient across the liposomal bilayer, thereby facilitating active loading of the agent into the liposomal aqueous core. Third, at a physiological pH of 7 or above (the pH to be encountered following drug release at the tumor site), the nucleophilicity of the amine manifests itself and cyclization to the C-21 carbonyl carbon occurs. This cyclization triggers a rapid and convenient nonenzymatic decomposition process that releases active camptothecin. Accordingly, this novel liposomal approach offers a potential system for tumor-targeting prodrugs of many water-insoluble camptothecins, including the highly lipophilic and clinically attractive analogues SN-38, 9-nitrocamptothecin and DB-67. The rate of formation of the active agent at the tumor site can be controlled through the selection of n (the length of the alkyl spacer group). Copyright © 2002 American Chemical Society.
引用
收藏
页码:7650 / 7651
页数:2
相关论文
共 13 条
  • [1] ARUN B, 1989, EXPERT OPIN PHARMACO, V246, P1046
  • [2] Liposome application: problems and prospects
    Barenholz, Y
    [J]. CURRENT OPINION IN COLLOID & INTERFACE SCIENCE, 2001, 6 (01) : 66 - 77
  • [3] Burke TG, 2000, ANN NY ACAD SCI, V922, P36
  • [4] Prodrug strategies in cancer therapy
    Denny, WA
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2001, 36 (7-8) : 577 - 595
  • [5] Garzon-Aburbeh A., 1990, [No title captured], Patent No. 4943579
  • [6] KAWATO Y, 1991, CANCER RES, V51, P4187
  • [7] Liehr J., 2000, ANN NY ACAD SCI, V922, P1
  • [8] Factors influencing uptake and retention of amino-containing drugs in large unilamellar vesicles exhibiting transmembrane pH gradients
    Maurer-Spurej, E
    Wong, KF
    Maurer, N
    Fenske, DB
    Cullis, PR
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1999, 1416 (1-2): : 1 - 10
  • [9] Irinotecan dosing:: Does the CPT in CPT-11 stand for "Can't predict toxicity"?
    Ratain, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) : 7 - 8
  • [10] Effective irinotecan (CPT-11)-containing liposomes: Intraliposomal conversion to the active metabolite SN-38
    Sadzuka, Y
    Hirotsu, S
    Hirota, S
    [J]. JAPANESE JOURNAL OF CANCER RESEARCH, 1999, 90 (02): : 226 - 232